|  |  |  |  |
| --- | --- | --- | --- |
| **Table 1:** Subject and injury characteristics of patients included in our analysis and enrolled in the Sygen trial and Murnau study, respectively. | | | |
|  | **Sygen trial** | **Murnau study** | **p- value** |
| *Subject characteristics* | | |  |
| Total, n | 703 | 239 |  |
| Sex, n (%) | | | 0.786 |
| Male | 560 (79.7) | 193 (80.8) |  |
| Female | 143 (20.3) | 46 (19.2) |  |
| Age in years at injury | | | **< 0.001** |
| Mean ± SD | 33 ± 14 | 51 ± 19 |  |
| *Neurological/functional outcomes* | | |  |
| Baseline ASIA impairment scale, n (%) | | | **< 0.001** |
| A | 446 (63.4) | 81 (33.9) |  |
| B | 77 (11.0) | 22 (9.2) |  |
| C | 149 (21.2) | 26 (10.9) |  |
| D | 31 (4.4) | 110 (46.0) |  |
| Lower extremity motor score, mean ± SD | | |  |
| Baseline | 2.82 ± 7.3 | 19.5 ± 19.9 | **< 0.001** |
| After one year | 12.8 ± 19.3 | 28.1 ± 21.9 | **< 0.001** |
| NA, n | 140 | 105 |  |
| *Blood markers*, n | 47 | 39 |  |